EyePoint Pharmaceuticals, Inc. (EYPT) Revenue History
Annual and quarterly revenue from 2003 to present
EYPT Revenue Over Time (2003–2025)
EYPT Revenue Growth History
15 of 22 years with positive growth- FY2003 revenue growth
- N/A
- FY2004 revenue growth
- +256.7%
- FY2005 revenue growth
- +137.4%
- FY2006 revenue growth
- +132.8%
- FY2007 revenue growth
- +52.5%
- FY2008 revenue growth
- +55.5%
- FY2009 revenue growth
- +249.9%
- FY2010 revenue growth
- +89.5%
- FY2011 revenue growth
- -78.5%
- FY2012 revenue growth
- -29.0%
- FY2013 revenue growth
- -39.2%
- FY2014 revenue growth
- +62.1%
- FY2015 revenue growth
- +664.9%
- FY2016 revenue growth
- -93.9%
- FY2017 revenue growth
- +365.4%
- FY2018 revenue growth
- -60.7%
- FY2019 revenue growth
- +587.8%
- FY2020 revenue growth
- +69.1%
- FY2021 revenue growth
- +7.3%
- FY2022 revenue growth
- +12.1%
- FY2023 revenue growth
- +11.1%
- FY2024 revenue growth
- -6.0%
- FY2025 revenue growth
- -27.5%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $696K | -97.2% |
| Q4 2025 | $620K | -94.6% |
| Q3 2025 | $966K | -90.8% |
| Q2 2025 | $5.3M | -43.7% |
| Q1 2025 | $24.5M | +109.3% |
| Q4 2024 | $11.6M | -17.4% |
| Q3 2024 | $10.5M | -30.8% |
| Q2 2024 | $9.5M | +4.1% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2024)
EYPT's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
EYPT Revenue Analysis (2003–2025)
Current Revenue & Growth
As of June 22, 2026, EyePoint Pharmaceuticals, Inc. (EYPT) generated trailing twelve-month (TTM) revenue of $7.6 million, reflecting significant decline in growth of -97.2% year-over-year. The most recent quarter (Q1 2026) recorded $696,000 in revenue, up 12.3% sequentially.
Historical Growth Trajectory
EYPT's 5-year compound annual growth rate (CAGR) stands at -1.8%, indicating revenue contraction over this period. The 3-year CAGR of -8.8% is below the 5-year average, signalling a growth deceleration in recent years. EyePoint Pharmaceuticals, Inc.'s highest annual revenue of $46.0 million was recorded in 2023.
Revenue by Segment
EYPT's revenue is primarily driven by License And Collaboration Agreement (83%), Product (7%), and Y U T I Q Product (7%). With over half of revenue concentrated in License And Collaboration Agreement, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including OCUL (-12.8% YoY), and NVCR (+8.5% YoY) — EYPT has underperformed the peer group in revenue growth. Compare EYPT vs OCUL →
EYPT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EYPTCurrent | $8M | -97.2% | -1.8% | -776.0% | |
 OCUL | $52M | -12.8% | +24.4% | -521.0% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% |
EYPT Historical Revenue Data (2003–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $31.4M | -27.5% | $29.3M | 93.4% | $-243,434,000 | -776.0% |
| 2024 | $43.3M | -6.0% | $39.6M | 91.4% | $-145,854,000 | -337.1% |
| 2023 | $46.0M | +11.1% | $41.4M | 89.9% | $-75,067,000 | -163.1% |
| 2022 | $41.4M | +12.1% | $33.1M | 79.9% | $-99,637,000 | -240.6% |
| 2021 | $36.9M | +7.3% | $28.8M | 77.9% | $-55,276,000 | -149.6% |
| 2020 | $34.4M | +69.1% | $28.6M | 83.1% | $-37,290,000 | -108.3% |
| 2019 | $20.4M | +587.8% | $17.7M | 86.8% | $-47,861,000 | -235.0% |
| 2018 | $3.0M | -60.7% | $-15,541,000 | -524.9% | $-26,274,000 | -887.3% |
| 2017 | $7.5M | +365.4% | $7.5M | 100.0% | $-18,576,000 | -246.4% |
| 2016 | $1.6M | -93.9% | $805K | 49.7% | $-21,774,000 | -1344.1% |
| 2015 | $26.6M | +664.9% | $12.2M | 45.9% | $6.4M | 24.2% |
| 2014 | $3.5M | +62.1% | $3.4M | 97.8% | $-13,490,000 | -388.4% |
| 2013 | $2.1M | -39.2% | $-7,430,000 | -346.7% | $-12,031,000 | -561.4% |
| 2012 | $3.5M | -29.0% | $-3,479,000 | -98.7% | $-25,211,000 | -715.0% |
| 2011 | $5.0M | -78.5% | $-2,074,000 | -41.8% | $-10,003,000 | -201.5% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
23+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
EYPT — Frequently Asked Questions
Quick answers to the most common questions about buying EYPT stock.
Is EYPT's revenue growth accelerating or slowing?
EYPT revenue is declining -97.2% year-over-year. TTM revenue fell to $8M, contrasting with the 5-year CAGR of -1.8%. The reversal reflects either macro headwinds or company-specific challenges.
What is EYPT's revenue history from 2003 to 2026?
EyePoint Pharmaceuticals, Inc. (EYPT) revenue history spans 2003 to 2026. TTM revenue as of 2026 is $8M, growing at -97.2% YoY. The 5-year CAGR is -1.8%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is EYPT's long-term revenue growth rate (CAGR)?
EyePoint Pharmaceuticals, Inc.'s 5-year revenue CAGR of -1.8% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -97.2% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for EYPT.
Why does EYPT's quarterly revenue fluctuate?
EYPT quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. EyePoint Pharmaceuticals, Inc.'s revenue data from 2003 to 2026 shows full historical quarterly detail on this page.
How is EYPT's revenue distributed by segment?
EYPT reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does EYPT's revenue compare to industry peers?
EyePoint Pharmaceuticals, Inc. (EYPT) with TTM revenue of $8M and -97.2% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.